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Objectives: To review the epidemiology of native septic arthritis to establish local guidelines for empirical anti-
biotic therapy as part of an antibiotic stewardship programme.
Methods: We conducted a 10 year retrospective study based on positive synovial fluid cultures and discharge
diagnosis of septic arthritis in adult patients. Microbiology results and medical records were reviewed.
Results: Between 1999 and 2008, we identified 233 episodes of septic arthritis. The predominant causative
pathogens were methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci (respectively, 44.6%
and 14.2% of cases). Only 11 cases (4.7%) of methicillin-resistant S. aureus (MRSA) arthritis were diagnosed,
among which 5 (45.5%) occurred in known carriers. For large-joint infections, amoxicillin/clavulanate or cefur-
oxime would have been appropriate in 84.5% of cases. MRSA and Mycobacterium tuberculosis would have been
the most frequent pathogens that would not have been covered. In contrast, amoxicillin/clavulanate would
have been appropriate for only 75.3% of small-joint infections (82.6% if diabetics are excluded). MRSA and
Pseudomonas aeruginosa would have been the main pathogens not covered. Piperacillin/tazobactam would
have been appropriate in 93.8% of cases (P,0.01 versus amoxicillin/clavulanate). This statistically significant
advantage is lost after exclusion of diabetics (P¼0.19).
Conclusions: Amoxicillin/clavulanate or cefuroxime would be adequate for empirical coverage of large-joint
septic arthritis in our area. A broad-spectrum antibiotic would be significantly superior for small-joint infections
in diabetics. Systematic coverage of MRSA is not justified, but should be considered for known carriers. These
recommendations are applicable to our local setting. They might also apply to hospitals sharing the same
epidemiology.
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Introduction
Septic arthritis represents the most serious condition in the
differential diagnosis of a hot swollen joint.1–4 The yearly inci-
dence of septic arthritis varies from 2 to 10 per 100000 patients
in the general population,2–5 but is up to 10 times higher in high-
risk patients such as those suffering from rheumatoid arthri-
tis.2,5,6 Pre-existing joint disease, diabetes, immunosuppressive
treatments, prosthetic joints, intravenous drug use, older age
and infection at a distant site are known risk factors.1–3,5 Attrib-
uted mortality ranges from 10% to 15%,7–9 mostly because of
concomitant bacteraemia with virulent microorganisms.2 Com-
plications are frequent (30%), including loss of joint function
subsequent to inflammation and release of lysosomal enzymes
and bacterial toxins.2,7–10 Several risk factors and delayed or
inadequate treatment worsen the outcome of septic arthritis.9,10
Thus, prompt initiation of adequate empirical treatment and
drainage of purulent joint fluid (either surgically or by closed-
needle aspiration) are of the utmost importance in reducing mor-
bidity and mortality.1
Clinical presentation of septic arthritis lacks specificity,
especially for patientswithunderlying joint disease. Thediagnostic
performance of signs and symptoms was recently reviewed, con-
cluding that history and physical examination are not able to sub-
stantially change the pretest probability of septic arthritis in
patients with an acutely painful, swollen joint.11 Sensitivity of
fever in particular is only 57%. Arthrocentesis is most helpful in
identifying septic arthritis. In particular, synovial white blood cell
# The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
J Antimicrob Chemother 2011; 66: 1168–1173
doi:10.1093/jac/dkr047 Advance Access publication 22 February 2011
1168
count and percentage of polymorphonuclear cells are the best
identifying factors for septic arthritis. Polymorphonuclear cell
count of at least 90% suggests infection with a likelihood ratio of
3.4 (95% confidence interval, 2.8–4.2). Gram’s stain sensitivity is
variable and has been estimated as ranging from 29% to 52%.11
Although analysis of synovial fluid may be useful in increasing
the pretest probability of septic arthritis, the initiation of empirical
antibiotic treatment is necessary while cultures are pending.
Guidelines for accurate and rapid management of suspected
septic arthritis have recently been published, with a proposal of
an empirical antibiotic regimen.12 These guidelines were mostly
based on expert opinion, owing to the paucity of well-designed
studies addressing the question of which empirical antibiotic
therapy would perform best for septic arthritis.13 The authors
suggested comparing these recommendations with the local
resistance pattern to ensure selection of an appropriate empirical
therapy,14 in accordance with guidelines for antibiotic
stewardship.15 While Staphylococcus aureus and streptococci
are commonly the most frequent pathogens in published
series,1–5,16,17 other microorganisms show an obvious geo-
graphical variation (e.g. brucellosis, tuberculosis).16,17 In addition,
although the distribution of microorganisms responsible for
septic arthritis has been reported as stable over time,18 the inci-
dence of multidrug-resistant microorganisms is generally
increasing, exhibiting remarkable geographical variability.19 In
particular, the frequency of methicillin-resistant S. aureus
(MRSA) and Pseudomonas aeruginosa infections is of concern
for empirical therapy of septic arthritis.
In an era of increasing bacterial resistance, the aim of our
study was to review the epidemiology of septic arthritis and
the antibiotic susceptibility profile of the predominant causative
pathogens in Western Switzerland in order to develop practice
guidelines for empirical antibiotic therapy.
Patients and methods
We conducted a retrospective study on consecutive adult patients
admitted with septic arthritis of a native joint in the University Hospital
of Lausanne, an 850-bed tertiary care hospital in Western Switzerland,
between January 1999 and December 2008. The design of this study
was in accordance with the ethical standards of our hospital Ethics
Committee.
Case definition
A case of adult native septic arthritis was defined as a .16 year-old
patient with a positive culture of synovial fluid and/or a discharge diag-
nosis of infectious arthropathy. Prosthetic joint arthritis was excluded.
Cases were identified by reviewing positive cultures of synovial fluid
samples in the microbiology database. Contaminations, bacteriological
samples wrongly labelled as synovial fluid or alternative diagnosis (e.g.
septic bursitis) were excluded. In addition, we reviewed hospital dis-
charge diagnosis codes of infectious arthropathies (ICD-10, v.2007,
codes M00.0–M01.1). Medical records of identified cases were assessed
to confirm the diagnosis of septic arthritis. Data on co-morbidities and
specific risk factors (namely diabetes, documented pre-existing joint
disease such as osteoarthritis or inflammatory arthritis, intravenous
drug use, joint surgery or intra-articular injection in the previous
3 months) were collected. Former MRSA carriage was recorded from
the infection control database. Hip, knee, shoulder, ankle, wrist, elbow,
sternoclavicular and sacroiliac joints were classified as large joints.
Joints of hands and feet were classified as small joints.
Microbiology
During the study period, Gram’s staining was systematically performed
on all synovial fluid samples. Samples were inoculated on standard
blood agar, chocolate agar, MacConkey agar and in thioglycolate broth.
The strains were identified at the species level using conventional pheno-
typic tests such as the Vitek2 system (BioMe´rieux, Marcy l’Etoile, France)
or the API system (BioMe´rieux). Antimicrobial susceptibility testing was
performed using manual disc diffusion methods according to CLSI (for-
merly NCCLS) guidelines or automated susceptibility testing using the
Vitek2 system (BioMe´rieux). When Mycobacterium tuberculosis arthritis
was suspected on the basis of history and medical examination, fluor-
escent microscopy was applied on synovial fluid samples using acid-fast
stain (auramine). MGIT broth (Becton Dickinson, Sparks, MD, USA) and
Lowenstein–Jensen medium were used for culture. Mycobacterial identi-
fication was performed using standard phenotypic and genotypic
methods. The automated blood culture system was the Bactec 9240
(Becton Dickinson) with the Plus aerobic/F and Lytic anaerobic/F vials
(Becton Dickinson).
Antibiotic susceptibility
Antibiotic susceptibility profiles including those for amoxicillin, amoxicil-
lin/clavulanate, cefuroxime, flucloxacillin and piperacillin/tazobactam of
causative pathogens were reviewed for each case. These antibiotics
were chosen according to the prescribing practice in our hospital and
recent guidelines.1,12 Our local antibiotic policy does not recommend
the use of quinolones and carbapenems as empirical choices.
During the study period, the proportion of MRSA in all clinical isolates
of S. aureus increased from 4% in 1999 to 12% in 2008 in our hospital
(mostly hospital-onset cases). The incidence of Gram-negative bacteria
producing extended-spectrum b-lactamases (ESBLs) was low (2% of all
Escherichia coli strains in 2009) and vancomycin-resistant enterococci
remained extremely rare (,1%).
Statistical analyses
Categorical variables were compared using the x2 or Fisher’s exact test
when appropriate; continuous variables were compared using the
Mann–Whitney test. Analyses were conducted using GraphPad Prism
software (v. 5.03).
Results
Cases and classification
During the 10 year study period, 233 cases of native septic arthri-
tis were diagnosed in 231 adult patients. Two intravenous drug
users (IVDUs) presented recurrent infections. One hundred and
seven episodes (45.9%) were identified through positive synovial
fluid cultures, and 126 (54.1%) additional cases through the hos-
pital discharge diagnosis codes. Among these 126 cases, 89 had
wrongly labelled positive synovial fluid cultures (samples mostly
named as surgical swabs without precision), 14 had synovial
samples that were processed in an external laboratory before
admission, 12 had positive concomitant blood cultures, 1 had
a negative synovial culture with a positive PCR and 10 remained
of unknown bacterial aetiology.
Most septic arthritis involved large joints (147 episodes, 63.1%).
Clinical characteristics of patients with large- and small-joint
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infections are presented in Table 1. Only four (1.7%) polyarticular
septic arthritis cases were observed, all involving large joints.
Based on the review of medical records, haematogenous
spread was the most likely pathogenesis for large-joint infections
(112 cases, 76.2%). Evolution from a contiguous focus (e.g.
osteomyelitis, soft tissue infection) was predominant in the
case of small-joint infections (81 cases, 94.2%). Small-joint
septic arthritis concerned mostly foot joints in diabetic patients
(33 out of 36 episodes, 91.7%).
Microbiology
As expected, the predominant causative pathogenswere S. aureus
(n¼115, 49.4%) and streptococci (n¼33, 14.2%). Aetiological
agents differed between large- and small-joint infections
(Table 2). Small-joint infections were more frequently polymicro-
bial (24.4% versus 1.4%, P,0.001). Only two cases of Neisseria
gonorrhoeae infections were diagnosed, both involving large
joints. In11patients, synovial fluidand/orother samples remained
negative, mostly because of concomitant antibiotic therapy. In
one of them, Streptococcus dysgalactiae was identified thanks to
a 16S rDNA broad-spectrum PCR. The other 10 cases remained
of undetermined aetiology (no PCR performed). Eleven out of
115 (9.6%) S. aureus isolates were methicillin resistant. Five
(45.5%) of the 11 MRSA cases occurred in known carriers.
A percutaneous synovial fluid sample was available in 107
cases (72.8%) of large-joint infections, and in 6 cases (7.0%) of
small-joint infections. Direct Gram’s staining and microscopy
were positive in only 33.6% of these 113 cases. In all cases of
M. tuberculosis arthritis (n¼7), auramine staining was negative.
M. tuberculosis-specific PCR was either negative or not performed.
Thirty-five episodes of septic arthritis (15.0%) occurred in
33 IVDUs. Among this subgroup of patients, methicillin-
susceptible S. aureus (MSSA) was by far the most commonly
involved pathogen (25 cases, 71.4%). No MRSA and only one
case of P. aeruginosa arthritis were observed.
Seventy episodes of septic arthritis (30.0% of all, 23.1% of
large- and 42.0% of small-joint infections) occurred in diabetic
patients. MSSA was also the main causative microorganism (28
cases, 40.0%). Gram-negative bacteria (namely two Escherichia
coli, one Enterobacter cloacae, three Morganella morganii, three
P. aeruginosa, one Pantoea spp. and two Proteus spp) were
responsible for 12 cases (17.1%). Eleven of these cases were
polymicrobial (15.7%).
Antibiotic susceptibility
Overall antibiotic susceptibility profiles of causative pathogens to
amoxicillin, amoxicillin/clavulanate, cefuroxime, flucloxacillin
and piperacillin/tazobactam were systematically reviewed
and are summarized in Table 3. No Gram-negative bacteria
produced ESBL.
Table 1. Comparison of clinical characteristics between patients with
large- and small-joint arthritis
Large joints
(n¼147)
Small joints
(n¼86) P value
Male gender 91 (61.9) 57 (66.3) 0.57
Mean age (years) 57.6 63.3 0.07
Co-morbidities
diabetes 34 (23.1) 36 (41.8) ,0.01
IVDU 28 (19.0) 7 (8.1) 0.04
pre-existing joint disease 62 (42.2) 56 (65.0) ,0.01
previous joint surgery/puncture 11 (7.5) 1 (1.2) 0.06
Localization
knee 57 (38.8) —
hip 26 (17.7) —
shoulder 24 (16.3) —
ankle 13 (8.8) —
wrist 13 (8.8) —
sternoclavicular 6 (4.1) —
elbow 3 (2.0) —
sacroiliac 1 (0.7) —
Hand
metacarpo-phalangeal — 12 (14.0)
distal interphalangeal — 9 (10.5)
proximal interphalangeal — 5 (5.8)
Foot
metatarso-phalangeal — 28 (32.6)
proximal interphalangeal — 27 (31.4)
distal interphalangeal — 5 (5.8)
Polyarticular 4 (2.7) 0
Data are n (%).
Table 2. Causative pathogens
Pathogen
Large joints
(n¼147)
Small joints
(n¼86)
Total
(n¼233)
S. aureus
MSSA 78 (53.1) 26 (30.2) 104 (44.6)
MRSA 8 (5.4) 3 (3.5) 11 (4.7)
Streptococcus spp. 20 (13.6) 13 (15.1) 33 (14.2)
Coagulase-negative staphylococci 3 (2.0) 3 (3.5) 6 (2.6)
Other Gram-positive bacteriaa 5 (3.4) 2 (2.3) 7 (3.0)
P. aeruginosa 4 (2.7) 7 (8.1) 11 (4.7)
E. colib 6 (4.1) 0 6 (2.6)
N. gonorrhoeae 2 (1.4) 0 2 (0.9)
Other Gram-negative bacteriab,c 7 (4.8) 6 (7.0) 13 (5.6)
M. tuberculosis 7 (4.8) 0 7 (3.0)
Polymicrobial 2 (1.4) 21 (24.4) 23 (9.9)
Unknown 5 (3.4) 5 (5.8) 10 (4.3)
Data are n (%).
aLarge-joint infections: two Propionibacterium acnes; three Streptococcus
pneumoniae (penicillin susceptible). Small-joint infections: one Enterococcus
spp. (vancomycin susceptible); one Corynebacterium spp.
bNo ESBL-producing Gram-negative bacteria.
cLarge-joint infections: two Neisseria spp.; one Proteus vulgaris; one
Pantoea spp.; one Haemophilus influenzae; one E. cloacae; one Brucella
spp. Small-joint infections: three M. morganii; one E. cloacae; one
Fusobacterium nucleatum; one Proteus mirabilis.
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Performances of various empirical antibiotic therapies
For large-joint infections, amoxicillin/clavulanate or cefuroxime
would have been appropriate in 84.5% of cases (Table 4).
MRSA (eight cases) and M. tuberculosis (seven cases) would
have been the most frequently uncovered pathogens. Addition
of vancomycin in previously known MRSA carriers (four patients)
would have only slightly increased the global appropriateness to
87.3%. An anti-pseudomonal penicillin (piperacillin/tazobactam)
would not have performed significantly better (88.0%, P¼0.4
versus amoxicillin/clavulanate or cefuroxime). Exclusion of
M. tuberculosis cases would increase the appropriateness of
empirical amoxicillin/clavulanate or cefuroxime to 88.8%.
In contrast, empirical amoxicillin/clavulanate would have
been appropriate in only 75.3% of all small-joint infections.
This rate would increase to 82.6% if diabetic patients were
excluded. MRSA (three cases, of which one occurred in a pre-
viously known carrier) and P. aeruginosa (nine cases, of which
seven were monomicrobial) would have been the main patho-
gens not covered. Piperacillin/tazobactam would have been
appropriate in 93.8% of cases of small-joint infections (P,0.01
versus amoxicillin/clavulanate). This statistically significant
advantage is lost after exclusion of diabetic patients (P¼0.19
versus amoxicillin/clavulanate). When considering only diabetic
patients with small-joint infections, piperacillin/tazobactam was
appropriate in 94.3% of cases versus 65.7% for amoxicillin/
clavulanate (P¼0.01).
Discussion
In order to establish guidelines for empirical antibiotic therapy,
we reviewed the epidemiology of septic arthritis over the last
10 years in Western Switzerland and assessed the overall anti-
biotic susceptibility profile of causative pathogens. Two
hundred and thirty-three consecutive cases were analysed.
Owing to the high proportion of wrongly labelled synovial fluid
specimens, the additional review of hospital discharge diagnosis
codes identified 54% of all cases and should therefore be
included in an exhaustive review process. Most of the previous
large series were published in the 1980s and 1990s,4,5,7,9,10,16
and only scarce recent data are available.8,17,18 Globally, the
main pathogens are concordant with previous studies,1–5,8–10
staphylococci and streptococci being the most frequently recov-
ered microorganisms. Incidence and species of Gram-negative
pathogens differed between large- and small-joint septic arthritis
and according to underlying co-morbidities such as diabetes.
Gonococcal and mycobacterial arthritis were rare in our
setting. Mycobacterial infections were included in our analysis
as the clinical presentation of this pathogen may be indistin-
guishable from other causes of septic arthritis.20 Only 10 septic
arthritis cases (4.3%) remained of undetermined aetiology.
Although we could not definitely conclude that they were infec-
tious arthritis, many previous studies of septic arthritis include
cases of unknown origin,5,6,10,16,17 probably secondary to pre-
vious antibiotic therapy.
Based on our local epidemiology, amoxicillin/clavulanate or
cefuroxime is adequate for empirical treatment of large-joint
septic arthritis and can be recommended in local guidelines.
An anti-pseudomonal antibiotic was not superior in this
setting. In contrast, piperacillin/tazobactam performs signifi-
cantly better in the subgroup of diabetic patients with small-joint
infections, mostly due to the higher incidence of P. aeruginosa.
We could not reliably consider the possible impact of previous
antibiotic therapy or recent hospitalization due to frequently
missing information in medical records. In diabetic patients
with small-joint infections, most cases arose from a contiguous
focus (100%, soft tissue and/or osteomyelitis) and concerned
foot joints (91.7%). This argues for chronic infections and poss-
ible previous outpatient antibiotic treatment. The use of a broad-
spectrum antibiotic in this specific clinical setting is in agreement
with recommendations of empirical therapy for severe diabetic
foot infections.21–23 Further data are needed to determine
whether narrower spectrum antibiotic therapy may be adequate
for diabetic patients with small-joint acute infections without
previous antibiotic therapy.
Septic arthritis due to MRSA also remained rare during the
study period (11 cases, 4.7% of all episodes). Although resistant
strains emerged soon after the introduction of methicillin in 1961
and progressively became endemic worldwide,24 many series
published between 1976 and 2007 do not mention the quanti-
tative importance of MRSA in the setting of S. aureus arthri-
tis.1,5,6,8–10,16,17 Only some studies performed in high MRSA
incidence areas report a proportion of septic arthritis due to
MRSA ranging from 2% to 25% of all cases.18,25–27 As clinical
presentation, patient demographics and co-morbidities do not
reliably distinguish MRSA from MSSA septic arthritis,27 guidelines
for empirical antibiotic therapy have to consider the local epide-
miology. Almost half of our cases were known carriers before the
Table 4. Performance of empirical antibiotic therapy on coverage of
causative pathogens
Location
Amoxicillin/
clavulanic acid
Piperacillin/
tazobactam P value
Large joints 120/142 (84.5) 125/142 (88.0) 0.4
Small joints 61/81 (75.3) 76/81 (93.8) ,0.01
diabetics 23/35 (65.7) 33/35 (94.3) ,0.01
non-diabetics 38/46 (82.6) 43/46 (93.5) 0.19
All 182/223 (81.6) 201/223 (90.1) 0.01
Data are n (%).
Table 3. Overall antibiotic susceptibility profiles of causative pathogensa
Antibiotic
Large joints
(n¼142)
Small joints
(n¼81)
Total
(n¼223)
Amoxicillin 45 (31.7) 27 (33.3) 72 (32.3)
Amoxicillin/clavulanic acid 120 (84.5) 62 (76.5) 182 (81.6)
Cefuroxime 120 (84.5) 59 (72.8) 179 (80.3)
Flucloxacillin 107 (75.4) 54 (66.7) 161 (72.2)
Piperacillin/tazobactam 125 (88.0) 76 (93.8) 201 (90.1)
Data are n (%).
aTen septic arthritis cases remained of unknown aetiology and were
excluded from this analysis (five large-joint and five small-joint
infections).
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septic arthritis. This is in agreement with studies demonstrating
the significant risk of subsequent infections in prevalent MRSA
carriers.28,29 If the incidence of MRSA septic arthritis does not
justify systematic empirical coverage of this pathogen in our
setting, an adapted empirical treatment should be considered
for known carriers.
Evaluation of septic arthritis in IVDUs showed that MSSA
remained the leading aetiological agent. P. aeruginosa septic
arthritis has been reported mostly in small studies of heroin
addicts from the 1980s.30,31 At that time, usage of pentazocine,
a synthetic opiate dissolved and injected without heating, was
frequently associated with bacteraemia due to environmental
bacteria such as P. aeruginosa. The parenteral usage of pentazo-
cine ended in 1983 when the manufacturer added naloxone to
stop its narcotic use.32 A series of 180 sternoclavicular infections,
a frequent localization in IVDUs, reported a drop in the
P. aeruginosa arthritis rate (from 82% before 1981 to 14%
after 1981) and its concomitant substitution by S. aureus infec-
tions.33 Our results are in agreement with this general trend
and allow us not to consider empirical coverage of P. aeruginosa
in IVDUs. Although intravenous drug use has been locally recog-
nized as a risk factor for infection with community-associated
MRSA,34 our data do not provide any evidence for dissemination
of this pathogen in our population of IVDUs.
By definition, our recommendations are only applicable to our
local setting, although they might also apply to hospitals sharing
the same epidemiology of resistant pathogens. Owing to the ret-
rospective design of our study, a precise description of the clinical
initial presentation and a meticulous review of some risk factors
were not possible. In particular, we could not integrate
the detailed immunosuppressive medication or anamnestic
elements indicating a previous urinary bacteraemia or risk
factors for sexually transmitted diseases. Usage of broad-
spectrum and pathogen-specific PCR for negative synovial fluid
cultures was not systematically available. However, this should
not have biased our analysis in minimizing resistant pathogens.
In summary, this 10 year review of the epidemiology of septic
arthritis in Western Switzerland allowed us to extrapolate an
appropriate empirical therapy for this local setting. These rec-
ommendations are only applicable to our local setting, although
they might also apply to hospitals sharing the same epidemiol-
ogy of resistant pathogens. Due to the changing incidence of
resistant pathogens over time, the adequacy of this proposal
should be validated on a regular basis.
Acknowledgements
We thank Ms Johanne Chevalier Parisod for her help in the review of
hospital discharge diagnosis codes of infectious arthropathies.
Funding
This work was carried out as part of the routine work in our
establishment.
Transparency declarations
None to declare.
References
1 Mathews CJ, Weston VC, Jones A et al. Bacterial septic arthritis in
adults. Lancet 2010; 375: 846–55.
2 Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002; 15:
527–44.
3 Pioro MH, Mandell BF. Septic arthritis. Rheum Dis Clin North Am 1997;
23: 239–58.
4 Ryan MJ, Kavanagh R, Wall PG et al. Bacterial joint infections in England
and Wales: analyses of bacterial isolates over a four year period. British J
Rheum 1997; 36: 370–3.
5 Kaandorp CJE, Dinant HJ, Van de Laar MA et al. Incidence and sources
of native and prosthetic joint infection: a community based prospective
survey. Ann Rheum Dis 1997; 56: 470–5.
6 Favero M, Schavon F, Riato L et al. Rheumatoid arthritis is the major risk
factor for septic arthritis in rheumatological settings. Autoimmun Rev
2008; 8: 59–61.
7 Kaandorp CJE, Krijnen P, Bernelot Moens HJ et al. The outcome of
bacterial arthritis. Arthritis Rheum 1997; 40: 884–92.
8 GuptaMN, Sturrock RD, FieldM. A prospective 2-year studyof 75 patients
with adult-onset septic arthritis. Rheumatology 2001; 40: 24–30.
9 Weston VC, Jones AC, Bradbury N et al. Clinical features and outcome
of septic arthritis in a single UK Health District 1982–1991. Ann Rheum
Dis 1999; 58: 214–9.
10 Cooper C, Cawley MID. Bacterial arthritis in an English health district: a
10 year review. Ann Rheum Dis 1986; 45: 458–63.
11 Margaretten ME, Kohlwes J, Moore D et al. Does this adult patient
have septic arthritis?. JAMA 2007; 297: 1478–88.
12 Coakley G, Mathews C, Field M et al. BSR & BHPR, BOA, RCGP and BSAC
guidelines for management of the hot swollen joint in adults.
Rheumatology 2006; 45: 1039–41.
13 Stengel D, Bauwens K, Sehouli J et al. Systematic review and
meta-analysis of antibiotic therapy for bone and joint infections. Lancet
Infect Dis 2001; 1: 175–88.
14 Weston V, Coakley G. Guideline for the management of the hot
swollen joint in adults with a particular focus on septic arthritis. J
Antimicrob Chemother 2006; 58: 492–3.
15 Dellit TH, Owens RC, McGowan JE et al. Infectious Diseases Society of
America and the Society for Healthcare Epidemiology of America
Guidelines for developing an institutional program to enhance
antimicrobial stewardship. Clin Infect Dis 2007; 44: 159–77.
16 Morgan DS, Fisher D, Merianos A et al. An 18 year clinical review of
septic arthritis from tropical Australia. Epidemiol Infect 1996; 117: 423–8.
17 Eder L, Zisman D, Rozenbaum M et al. Clinical features and etiology of
septic arthritis in northern Israel. Rheumatology 2005; 44: 1559–63.
18 Dubost JJ, Soubrier M, De Champs C et al. No changes in the
distribution of organisms responsible for septic arthritis over a 20 year
period. Ann Rheum Dis 2002; 61: 267–9.
19 Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its
potential impact on empirical therapy. Clin Microbiol Infect 2008; 14
Suppl 6: 2–8.
20 Harrington JT. Mycobacterial and fungal arthritis. Curr Opin Rheumatol
1998; 10: 335–8.
21 Wheat LJ, Allen SD, Henry M et al. Diabetic foot infections:
bacteriologic analysis. Arch Intern Med 1986; 146: 1935–40.
22 Lipsky BA, Berendt AR, Gunner Deery H et al. Diagnosis and treatment
of diabetic foot infections. Clin Infect Dis 2004; 39: 885–910.
23 Rao N, Lipsky BA. Optimizing antimicrobial therapy in diabetic foot
infections. Drugs 2007; 67: 195–214.
Clerc et al.
1172
24 Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus
in the antibiotic era. Nat Rev Microbiol 2009; 7: 629–41.
25 Gupta MN, Sturrock RD, Field M. Prospective comparative study of
patients with culture proven and high suspicion of adult onset septic
arthritis. Ann Rheum Dis 2003; 62: 327–31.
26 Ross JJ, Davidson L. Methicillin-resistant Staphylococcus aureus septic
arthritis: an emerging clinical syndrome. Rheumatology 2005; 44:
1197–8.
27 Al-Nammari SS, Bobak P, Venkatesh R. Methicillin resistant
Staphylococcus aureus versus methicillin sensitive Staphylococcus
aureus adult haematogenous septic arthritis. Arch Orthop Trauma Surg
2007; 127: 537–42.
28 Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus
infection after previous infection or colonization. Clin Infect Dis 2003;
36: 281–5.
29 Datta R, Huang SS. Risk of infection and death due to methicillin-
resistant Staphylococcus aureus in long term carriers. Clin Infect Dis
2008; 47: 176–81.
30 Brancos MA, Peris P, Miro JM et al. Septic arthritis in heroin addicts.
Semin Arthritis Rheum 1991; 21: 81–7.
31 Chandrasekar PH, Narula AP. Bone and joint infection in intravenous
drug abusers. Rev Infect Dis 1986; 8: 904–11.
32 Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on
the use and abuse of pentazocine. Public Health Rep 1987; 102: 426–9.
33 Ross JJ, Shamsuddin H. Sternoclavicular septic arthritis, review of 180
cases. Medicine 2004; 83: 139–48.
34 Huang H, Cohen SH, Monchaud C et al. Injecting drug use and
community-associated methicillin-resistant Staphylococcus aureus
infection. Diagn Microbiol Infect Dis 2008; 60: 347–50.
Adult native septic arthritis
1173
JAC
